Claims for Patent: 8,299,106
✉ Email this page to a colleague
Summary for Patent: 8,299,106
Title: | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
Abstract: | The present invention relates to novel thiazole-substituted indolin-2-ones as inhibitors of CSCPK and related kinases; to methods of inhibiting cancer stem cells by using a kinase inhibitor; to pharmaceutical compositions containing such compounds; and to methods of using such compounds in the treatment of a protein kinase related disorder in a mammal; and to processes of making such compounds and intermediates thereof. |
Inventor(s): | Li; Chiang Jia (Cambridge, MA), Liu; Ji-Feng (Winchester, MA), Li; Youzhi (Westwood, MA), Li; Wei (Wayland, MA), Rogoff; Harry (Wrentham, MA) |
Assignee: | Boston Biomedical, Inc. (Norwood, MA) |
Application Number: | 12/676,869 |
Patent Claims: | 1. A compound selected from the group consisting of: ##STR00024## ##STR00025## and an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or
solvate thereof.
2. A pharmaceutical composition comprising a compound or a pharmaceutically-acceptable salt thereof as claimed in claim 1 and a pharmaceutically-acceptable excipient, carrier, or diluent. 3. The pharmaceutical composition of claim 2, wherein the pharmaceutically-acceptable excipient, carrier, or diluent is a solution mixture or a suspension mixture comprising, by weight, about 12.5% of dimethylacetamide, about 52.5% of PEG400, and about 35% of 20% Vitamin E. 4. The pharmaceutical composition of claim 2, further comprising at least one other anti-cancer therapy agent. 5. The pharmaceutical composition of claim 4, wherein said anti-cancer therapy agent is at least one agent selected from the group consisting of radiotherapy (XRT) agents, cytotoxic agents, targeted agents, and adjunctive agents. 6. The pharmaceutical composition of claim 4 or 5, wherein said anti-cancer therapy agent is selected from the group consisting of gemcitabine, erlotinib, paclitaxel, docetaxel, carboplatin, cisplatin, 5-fluorouracil, doxorubicin, sorafenib, imatinib, bevacizumab, cetuximab, and trastuzumab. |
Details for Patent 8,299,106
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2027-09-06 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2027-09-06 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2027-09-06 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2027-09-06 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2027-09-06 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2027-09-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.